Nelson shared photos from outside No. 10 after months of public advocacy tied to her family’s experience with SMA, renewing calls to add the condition to the newborn heel-prick test. A current report on her Downing Street visit said the singer has continued meeting officials and raising awareness as the issue gains traction beyond entertainment headlines.
The campaign’s political weight is easy to measure. Her UK Parliament petition has already passed the threshold required for parliamentary consideration and, as of Tuesday, was still waiting for a debate date. That means the issue has moved from celebrity advocacy into a formal Westminster process, giving campaigners a chance to press for faster action in public.
There has also been a clear policy shift. In March, the government said the NHS was planning an in-service evaluation of SMA screening in England, a live NHS rollout designed to answer remaining questions before any permanent recommendation is made. That plan is now embedded in the NHS public health functions agreement for 2026-27, which says NHS England will establish SMA evaluation activity and implement the agreed elements across parts of England.
Supporters say the tone changed again this month. In an April update on the accelerated screening rollout, Nelson said the in-service evaluation in England is now due to begin in October 2026, earlier than previously expected. That has been welcomed as a real breakthrough, even as campaigners argue that a staggered start is not the same thing as universal screening.
The next formal milestone is already in view. England’s Rare Diseases Action Plan 2026 update says the UK National Screening Committee will consider the draft recommendation from the in-service evaluations for severe combined immunodeficiency and SMA. For families following the process closely, that means Tuesday’s Downing Street moment lands while the policy machinery is already moving.
Why the Jesy Nelson SMA campaign keeps finding traction
SMA is a rare genetic condition that causes progressive muscle weakness and can affect movement, breathing and swallowing. Campaigners have long argued that the case for screening is strongest before symptoms appear, when treatment can begin sooner and potentially preserve more function. That is why the push to add SMA to the heel-prick test has become one of the clearest rare-disease screening debates in the UK.
Nelson’s profile has undeniably widened the audience, but the issue did not start with her. Long before this year’s headlines, families, clinicians and charities were already trying to push the screening system forward. In an August 2023 UK NSC update, officials said they wanted both a fresh modelling study and scoping work for an in-service evaluation, a sign that the case had already advanced beyond a preliminary review.
The human frustration behind that process was captured again this year. A January report from The Guardian described how families affected by SMA said they had been calling for newborn screening for years, only to see the issue break through nationally after Nelson spoke publicly. That wider history helps explain why her campaign feels both newly urgent and deeply rooted.
It also explains why developments in Scotland have sharpened expectations elsewhere. With Scotland already moving ahead with newborn screening, campaigners in England can now point to a real UK example rather than a distant international one. That raises the pressure on ministers to show that the English evaluation will be more than a holding pattern.
What Downing Street changes, and what it does not
Tuesday’s visit matters because it places a technical screening debate at the center of government imagery. No. 10 is not where the clinical evidence will be decided, but it is where public pressure becomes harder to ignore. For a rare disease community used to arguing its case in specialist circles, that visibility counts.
Still, the campaign is not at its end point. An evaluation is not the same as permanent nationwide screening, and a partial rollout will continue to leave some families outside the system in the meantime. The real test now is whether ministers and NHS leaders can turn the current momentum into a timetable that feels fast enough for parents, credible enough for clinicians and comprehensive enough to end the postcode argument.
For Nelson, reaching Downing Street is a powerful symbol. For campaigners, it is something more practical: proof that a long-running fight over newborn SMA screening has reached the government’s front door, but still needs to make it through.
